摘要 ： 近日，中国医学科学院发布多批政府采购意向，仪器信息网特对其中的仪器设备品目进行梳理，统计出18项仪器设备采购意 向，预算总额达1.00亿元。 特别提示 微信机制调整，点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标，否则很可能无法看到我们的推送。 近日， 中国医学科学院发布 18 项仪器设备采购意向，预算总额达 1.00 亿 元，涉及 高通量光学蛋白分子互作检测 系统、超高效液相色谱串联四极杆质谱联用系统、高通量光学蛋白分子互作检测系统、超高效液相色谱串联四极杆质谱 联用系统 、全自动动物生化分析仪、全自动动物血液分析仪、高通量 全智能细胞制烤染稳定数据操作仪等，预计采购 时间为202 5 年 5~10 月。 部分采购仪器： 高通量光学蛋白分子互作检测系统 高通量光学蛋白分子互作检测系统是生命科学与生物制药领域的重要分析工具，基于生物层干涉（BLI）或表面等离子 体共振（SPR）等光学技术，实现实时、无标记、高精度的分子间相互作用检测，被誉为分子互作检测的"金标准"。 全自动动物生化分析仪 全自动动物生化分析仪是专为动物临床诊断和实验研究设计的高精度生化检测设备，主要用于动物血液、尿液等 ...

Core Viewpoint - The company reported a decline in revenue and net profit for the first half of 2025, but showed significant improvement in the second quarter, indicating a potential recovery in performance driven by the resumption of domestic procurement and new product launches [1][2]. Group 1: Financial Performance - In H1 2025, the company achieved revenue of 964 million yuan, a year-over-year decrease of 4.78%, and a net profit of 47 million yuan, down 72.43% year-over-year [1]. - Q2 2025 saw revenue of 534 million yuan, a slight year-over-year increase of 0.17% and a quarter-over-quarter increase of 24.24%, with net profit at 39 million yuan, down 44.65% year-over-year but up 382.45% quarter-over-quarter [1]. - The company’s gross margin decreased to 62.08%, down 5.35 percentage points, and net margin fell to 4.88%, down 11.96 percentage points [3]. Group 2: Market and Product Insights - The domestic bidding and procurement for medical devices are gradually recovering, leading to a significant improvement in Q2 performance, with expectations for continued growth in the second half of the year [2]. - The company’s ultrasound business generated revenue of 550 million yuan, down 9.87%, while the endoscope business saw revenue of 388 million yuan, up 0.08%, indicating overall stability [2]. - The company is focusing on high-intensity strategic investments in R&D and sales, with a sales expense ratio of 31.63% and R&D expense ratio of 25.31%, aimed at accelerating product upgrades and market expansion [3]. Group 3: Future Outlook - The company anticipates revenue growth from 2025 to 2027, with projected revenues of 2.318 billion, 2.712 billion, and 3.252 billion yuan, representing year-over-year growth rates of 15.09%, 17.00%, and 19.91% respectively [3]. - Expected net profits for the same period are 310 million, 454 million, and 598 million yuan, with year-over-year growth rates of 117.76%, 46.50%, and 31.68% respectively [3].